An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants

NCT ID: NCT02100111

Last Updated: 2017-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

134 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-01

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center, observational study involves reviewing the medical records of approximately 100 adult participants diagnosed with advanced BCC from 01 January 2005 until 31 December 2010. Participant records will be analyzed to identify participant characteristics, treatment patterns and clinical outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Basal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with advanced or metastatic BCC

Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* New diagnosis of advanced BCC, defined as (1) locally advanced BCC (inoperable as determined by the site investigator or surgery contraindicated) with receipt of radiation therapy (unless radiation was contraindicated), or (2) metastatic BCC, from 01 January 2005 through 31 December 2010

Exclusion Criteria

* Participation in an interventional trial that dictated treatment during the study time period (01 January 2005 - 31 December 2010), or within 90 days prior to individual participant' study enrolment dates
* Participants undergoing treatment with a Hedgehog pathway inhibitor
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hotel Dieu; Dermatologie

Angers, , France

Site Status

Hopital Prive D Antony; Dermatologie

Antony, , France

Site Status

Hôpital St Jacques de Besançon; (Dermatology)

Besançon, , France

Site Status

Hopital Saint Andre CHU De Bordeaux; Dermatologie

Bordeaux, , France

Site Status

Hopital Ambroise Pare; Sce Dermatologie

Boulogne-Billancourt, , France

Site Status

Hopital La Cavale Blanche; Medecine 1

Brest, , France

Site Status

Chu Estaing; Dermatologie

Clermont-Ferrand, , France

Site Status

Hopital Victor Jousselin; Dermatologie

Dreux, , France

Site Status

Chi Emile Durkheim Site Epinal; Oncologie

Épinal, , France

Site Status

Hôpital Albert Michallon; Derm Phlebologie Allergologie

Grenoble, , France

Site Status

Hopital Saint Vincent; Consult Dermatologie Enfants

Lille, , France

Site Status

Hopital Claude Huriez; Sce Dermatologie

Lille, , France

Site Status

Hopital Dupuytren; Dermatologie

Limoges, , France

Site Status

Hopital Timone Adultes; Radiotherapie Oncologie

Marseille, , France

Site Status

Hopital Jacques Monod; Dermatologie

Montivilliers, , France

Site Status

Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie

Montpellier, , France

Site Status

Hopital Bichat Claude Bernard; Sce Dermatologie

Paris, , France

Site Status

Hopital Saint Louis; Dermatologie 1

Paris, , France

Site Status

Hopital de Haut-Leveque; Dermatologie Serv.

Pessac, , France

Site Status

Centre Hospitalier Lyon Sud; Dermatologie

Pierre-Bénite, , France

Site Status

Chu La Miletrie; Dermatologie

Poitiers, , France

Site Status

Hopital Laennec; Sce Dermatologie

Quimper, , France

Site Status

Hopital Nord ; Dermatologie

Saint-Etienne, , France

Site Status

Hopital Sud; Dermatologie

Salouël, , France

Site Status

Hopitaux de Brabois; Dermatologie

Vandœuvre-lès-Nancy, , France

Site Status

HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie

Erfurt, , Germany

Site Status

Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie

Frankfurt, , Germany

Site Status

SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie

Gera, , Germany

Site Status

Universitätsmedizin Greifswald; Klinik für Mund-Kiefer-Gesichtschirurgie/Plastische Operationen

Greifswald, , Germany

Site Status

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik

Mainz, , Germany

Site Status

Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie

Mannheim, , Germany

Site Status

Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie

München, , Germany

Site Status

Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie

Quedlinburg, , Germany

Site Status

Irccs Crob

Rionero in Vulture, Basilicate, Italy

Site Status

Arcispedale Santa Maria Nuova; Dermatologia

Reggio Emilia, Emilia-Romagna, Italy

Site Status

Spedali Civili di Brescia

Brescia, Lombardy, Italy

Site Status

Università del Piemonte Orientale; Dipartimento di Dermatologia

Novara, Piedmont, Italy

Site Status

Policlinico Le Molinette; Clinica Dermatologica

Turin, Piedmont, Italy

Site Status

Azienda Sanitaria di Firenze Presidio Palagi - SC Dermatologia II e Fisioterapia Dermatologica

Florence, Tuscany, Italy

Site Status

A.O. Univ. Senese Policlinico S. Maria alle Scotte; Dip. Medicina clinica e Scienze Immunologiche

Siena, Tuscany, Italy

Site Status

Western Infirmary; Division of Cardiovascular and Medical Sciences

Glasgow, , United Kingdom

Site Status

Manchester Royal Infirmary; Department Of Medicine

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Italy United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MO28682

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

L19IL2/L19TNF in Skin Cancer Patients
NCT05329792 UNKNOWN PHASE2